HIGHLIGHTS
- who: . and collaborators from the Hackensack Meridian Health, United States Guangxi Medical University, China have published the research: TIDE: adjuvant tislelizumab plus donafenib combined with transarterial chemoembolization for high-risk hepatocellular carcinoma after surgery: protocol for a prospective, single-arm, phase II trial, in the Journal: (JOURNAL)
- what: The aim of this study is to observe and evaluate the efficacy and safety of the adjuvant therapy regimen of donafenib and tislelizumab combined with TACE in patients with a high risk of HCC recurrence after resection.
- how: These results indicated that further exploration of . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.